CHITOGENX CLOSES $288,000 SECOND TRANCHE OF NON-BROKERED PRIVATE PLACEMENT OFFERING
- Debt further reduced following reinvestments into Offering
- Proceeds to be used to advance ongoing R&D programs and pursue a development/strategic partnership agreement
- Corrections to press release issued on May 5, 2023
MONTREAL, June 5, 2023 /CNW/ - ChitogenX Inc., (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced the closing of a $288,000 second tranche of its previously announced non-brokered private placement offering of units (the "Offering"). The second tranche of the Offering consists of gross cash proceeds of $41,250 and $247,141 in debt conversions from holders of convertible debentures which matured on May 1, 2023 ("Debentures"). One insider converted accrued and unpaid interest on Holders of debentures that matured on May 1, 2023, for an amount of $107,250.
The Company issued 1,922,608 Units at a price of $0.15 per Unit for a total consideration of $288,391.40. Each Unit consist of one class A share of the Company (each, a "Share") and one share purchase warrant of the Company (each whole share purchase warrant, a "Warrant"). Each Warrant entitles the holder to purchase one Share of the Company (each, a "Warrant Share") at a price of $0.35 per Warrant Share for a period of 36 months from closing (the "Closing Date"), subject to adjustment in certain events. If, at any time following the Closing Date, the daily volume weighted average trading price of the Shares on the Canadian Securities Exchange is greater than $0.50 per Share for the preceding 10 consecutive trading days, the Company shall have the right to accelerate the expiry date of the Warrants to a date that is at least 30 days following the date of such notice to holders of Warrants.
The Company will use the net proceeds of the Offering to:
- Pursue development/strategic partnership agreement for leveraging the Company's proprietary platform for regenerative medicine applications,
- Complete enrollment for the Rotator Cuff Tear Repair U.S. phase I/II clinical trial program,
- Complete proof of concept work for Meniscus repair, and
- Leverage Polytechnique partnership and recent non-dilutive grants to drive proof of concept in additional high-potential indications.
The Common Shares and the Warrants are subject to a statutory 4-month hold period under the applicable securities laws and in such case the certificates evidencing the Shares and the Warrants will bear a legend to that effect, as applicable.
Participation of insiders of the Company in the Private Placement constitutes a "related party transaction" as defined under Regulation 61-101 respecting Protection of Minority Security Holders in Special Transactions ("Regulation 61-101"). The Company intends to rely on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(g) and 5.7(e) of Regulation 61-101 on the basis of the Company's financial difficulties as it attempts to reduce debt and facilitate the implementation of a recovery plan. A material change report was not filed in connection with the participation of the insiders at least 21 days in advance of the closing of the Private Placement, which the Company deemed reasonable in the circumstances, in order to close the transaction as soon as practicable to enable it to use the funds.
The Company wishes to clarify and amend its disclosure regarding the closing of the first tranche of its amended non-brokered private placement offering of units for $3.86 million contained in the May 5, 2023, press release with respect to total gross proceeds received. The first tranche of the Offering consisted of gross cash proceeds of $1,267,000 and debt conversions of $2,589,348.80 for a total consideration of $3,856,348.80. Furthermore, the news release stated that the Company relied on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(a) of Regulation 61-101 on the basis that participation in the Private Placement by insiders did not exceed 25% of the fair market value of the Company's market capitalization. The Company in fact relied on the exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(g) and 5.7(e) of Regulation 61-101 on the basis of its financial difficulties, as indicated above.
ChitogenX Inc. is a clinical stage regenerative medicine company dedicated to the development of novel therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary ORTHO-R technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various Regenerative Medicine Applications.
Other formulations are being developed to leverage the technology's performance characteristics such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease. Further information about ChitogenX is available on the Company's website at www.chitogenx.com and on SEDAR at www.sedar.com.
This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE ChitogenX Inc.
Company, Philippe Deschamps, President and Chief Executive Officer, 614-596-2597, [email protected]; or Luc Mainville, Senior Vice-president and Chief Financial Officer, 514-693-8854, [email protected]; Investors, Frederic Dumais, Director Communications and Investor Relations, (514) 261-4735, [email protected]
Share this article